Angiodynamics Inc (ANGO)

$11.04 +0.05 (0.45%)
Market Cap 452.98M
Revenue (ttm) 292.50M
Net Income (ttm) -33.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -11.62%
Debt to Equity Ratio 0.00
Volume 211,200
Avg Vol 569,822
Day's Range N/A - N/A
Shares Out 41.22M
Stochastic %K 49%
Beta 0.48
Analysts Strong Sell
Price Target $19.33

Company Profile

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy sy...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 518 795 1400
Address:
14 Plaza Drive, Latham, United States
ZacksResearch
ZacksResearch Mar. 11 at 4:43 PM
Why $ANGO's growth story is just beginning! 🚀 With $ANGO's NanoKnife seeing revenue jump 22.2% YoY, driven by prostate cancer procedure adoption. Plus, the Auryon franchise reported its 18th straight quarter of double-digit growth in the second quarter. Discover why ANGO could continue to outperform 👉 https://www.zacks.com/stock/news/2882503/reasons-to-add-angiodynamics-stock-to-your-portfolio-for-now?cid=sm-stocktwits-2-2882503-body-37022&ADID=SYND_STOCKTWITS_TWEET_2_2882503_BODY_37022
0 · Reply
ZacksResearch
ZacksResearch Mar. 11 at 3:43 PM
$ANGO is gaining serious momentum — and the story might just be getting started. 👀 Strong fiscal Q2 results, surging NanoKnife adoption in prostate cancer, and broad Med Tech growth are all helping support margins and strengthen the investment case. See why ANGO could deserve a spot in your portfolio 👉 https://www.zacks.com/stock/news/2882503/reasons-to-add-angiodynamics-stock-to-your-portfolio-for-now?cid=sm-stocktwits-2-2882503-teaser-37012&ADID=SYND_STOCKTWITS_TWEET_2_2882503_TEASER_37012
0 · Reply
Estimize
Estimize Mar. 11 at 10:03 AM
Wall St is expecting -0.11 EPS for $ANGO Q3 [Reporting 04/02 BMO] http://www.estimize.com/intro/ango?chart=historical&metric_name=eps&utm_c
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 4 at 12:51 PM
$ANGO RSI: 50.52, MACD: 0.0938 Vol: 0.38, MA20: 11.05, MA50: 11.26 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ZacksResearch
ZacksResearch Feb. 23 at 6:14 PM
$ANGO just widened its oncology footprint in Europe — and that’s a big deal. AngioDynamics expanded NanoKnife’s EU indications to include liver, pancreas, kidney and prostate tumors, significantly broadening its reach and growth runway in multi-organ tumor ablation. That’s meaningful expansion, not incremental progress. Could this unlock the next leg of growth? Get the full breakdown 👉 https://www.zacks.com/stock/news/2873809/ango-expands-nanoknife-in-europe-for-multi-organ-tumor-ablation?cid=sm-stocktwits-2-2873809-teaser-34767&ADID=SYND_STOCKTWITS_TWEET_2_2873809_TEASER_34767
0 · Reply
ZacksResearch
ZacksResearch Feb. 23 at 5:14 PM
$ANGO gains on expanded NanoKnife approval in Europe! 🚀 Broader approvals for liver, pancreas, kidney, and prostate tumors open up significant market potential, reinforcing NanoKnife as a versatile oncology platform. 📈 With Europe contributing to 28% of global IRE volumes, ANGO is set for growth. Discover the full story here 👉 https://www.zacks.com/stock/news/2873809/ango-expands-nanoknife-in-europe-for-multi-organ-tumor-ablation?cid=sm-stocktwits-2-2873809-body-34751&ADID=SYND_STOCKTWITS_TWEET_2_2873809_BODY_34751
0 · Reply
TheWolfOfSanFran
TheWolfOfSanFran Feb. 23 at 2:50 AM
$ANGO m&A target possibly. 👀
0 · Reply
Estimize
Estimize Feb. 19 at 11:24 PM
Wall St is expecting -0.11 EPS for $ANGO Q3 [Reporting 04/02 BMO] http://www.estimize.com/intro/ango?chart=historical&metric_name=eps&utm_c
0 · Reply
OpenOutcrier
OpenOutcrier Feb. 19 at 2:01 PM
$ANGO (+2.4% pre) AngioDynamics gains European approval for NanoKnife tumor treatment https://ooc.bz/l/93907
0 · Reply
DARKP00L
DARKP00L Feb. 19 at 1:49 PM
$ANGO 08:43 on Feb. 19 2026 AngioDynamics Expands European Indications For NanoKnife System To Include Soft Tissue Ablation For Tumors Of Liver, Pancreas, Kidney, And Prostate #tradeideas
0 · Reply
Latest News on ANGO
AngioDynamics to Present at the Leerink Partners Global Healthcare Conference

Feb 23, 2026, 4:30 PM EST - 16 days ago

AngioDynamics to Present at the Leerink Partners Global Healthcare Conference

AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform

Feb 19, 2026, 8:30 AM EST - 20 days ago

AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform

AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care

Feb 5, 2026, 8:00 AM EST - 4 weeks ago

AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care

AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance

Feb 3, 2026, 8:00 AM EST - 5 weeks ago

AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance

AngioDynamics, Inc. (ANGO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 8:16 PM EST - 2 months ago

AngioDynamics, Inc. (ANGO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

AngioDynamics, Inc. (ANGO) Q2 2026 Earnings Call Transcript

Jan 6, 2026, 10:18 AM EST - 2 months ago

AngioDynamics, Inc. (ANGO) Q2 2026 Earnings Call Transcript

AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability

Jan 6, 2026, 6:00 AM EST - 2 months ago

AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability

AngioDynamics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Dec 30, 2025, 6:51 AM EST - 2 months ago

AngioDynamics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

AngioDynamics: Growth Remains Under The Radar

Dec 29, 2025, 6:47 PM EST - 2 months ago

AngioDynamics: Growth Remains Under The Radar

AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026

Dec 23, 2025, 8:00 AM EST - 2 months ago

AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026

AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 22, 2025, 8:00 AM EST - 2 months ago

AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference

AngioDynamics, Inc. (ANGO) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 10, 2025, 10:31 AM EST - 4 months ago

AngioDynamics, Inc. (ANGO) Presents at UBS Global Healthcare Conference 2025 Transcript

AngioDynamics to Participate in the UBS Global Healthcare Conference

Oct 27, 2025, 4:30 PM EDT - 4 months ago

AngioDynamics to Participate in the UBS Global Healthcare Conference

AngioDynamics' NanoKnife® System Named to TIME's 2025 Best Inventions List

Oct 13, 2025, 8:30 AM EDT - 5 months ago

AngioDynamics' NanoKnife® System Named to TIME's 2025 Best Inventions List

AngioDynamics: Discounted Sales Multiple With Real Growth Engines

Oct 2, 2025, 3:00 PM EDT - 5 months ago

AngioDynamics: Discounted Sales Multiple With Real Growth Engines

AngioDynamics, Inc. (ANGO) Q1 2026 Earnings Call Transcript

Oct 2, 2025, 10:02 AM EDT - 5 months ago

AngioDynamics, Inc. (ANGO) Q1 2026 Earnings Call Transcript

Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results

Oct 2, 2025, 9:44 AM EDT - 5 months ago

Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results

AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum

Oct 2, 2025, 6:00 AM EDT - 5 months ago

AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum

Top Wall Street Forecasters Revamp AngioDynamics Expectations Ahead Of Q1 Earnings

Oct 1, 2025, 9:57 AM EDT - 5 months ago

Top Wall Street Forecasters Revamp AngioDynamics Expectations Ahead Of Q1 Earnings

AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025

Sep 18, 2025, 8:00 AM EDT - 6 months ago

AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025

AngioDynamics: A MedTech Powerhouse Emerging From Legacy Overhaul

Aug 17, 2025, 8:23 AM EDT - 7 months ago

AngioDynamics: A MedTech Powerhouse Emerging From Legacy Overhaul

AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference

Aug 6, 2025, 4:30 PM EDT - 7 months ago

AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference

AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia

Jul 28, 2025, 8:30 AM EDT - 8 months ago

AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia

AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology

Jul 23, 2025, 8:30 AM EDT - 8 months ago

AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology

AngioDynamics, Inc. (ANGO) Q4 2025 Earnings Call Transcript

Jul 15, 2025, 12:40 PM EDT - 8 months ago

AngioDynamics, Inc. (ANGO) Q4 2025 Earnings Call Transcript

AngioDynamics 'Exceptionally Well-Positioned' For 2026, CEO Says: But Tariffs Still Sting

Jul 15, 2025, 11:59 AM EDT - 8 months ago

AngioDynamics 'Exceptionally Well-Positioned' For 2026, CEO Says: But Tariffs Still Sting

AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth

Jul 15, 2025, 6:30 AM EDT - 8 months ago

AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth

AngioDynamics to Report Fiscal 2025 Fourth Quarter and Full-Year Financial Results on Tuesday, July 15, 2025

Jul 7, 2025, 8:00 AM EDT - 8 months ago

AngioDynamics to Report Fiscal 2025 Fourth Quarter and Full-Year Financial Results on Tuesday, July 15, 2025

AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary Embolism

Jun 23, 2025, 8:00 AM EDT - 9 months ago

AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary Embolism

Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance

Apr 2, 2025, 10:41 AM EDT - 1 year ago

Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance

AngioDynamics, Inc. (ANGO) Q3 2025 Earnings Call Transcript

Apr 2, 2025, 10:20 AM EDT - 1 year ago

AngioDynamics, Inc. (ANGO) Q3 2025 Earnings Call Transcript

AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results

Apr 2, 2025, 6:30 AM EDT - 1 year ago

AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results

AngioDynamics to Host Virtual Cardiovascular Investor Event

Mar 31, 2025, 8:00 AM EDT - 1 year ago

AngioDynamics to Host Virtual Cardiovascular Investor Event

AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event

Mar 19, 2025, 8:00 AM EDT - 1 year ago

AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event

AngioDynamics to Present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference

Mar 10, 2025, 4:30 PM EDT - 1 year ago

AngioDynamics to Present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference

AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia

Jan 30, 2025, 7:30 AM EST - 1 year ago

AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia

AngioDynamics: Improving Financial Performance And Good Clinical Data Reinvigorate The Shares

Jan 16, 2025, 5:07 AM EST - 1 year ago

AngioDynamics: Improving Financial Performance And Good Clinical Data Reinvigorate The Shares

AngioDynamics Announces Publication of APEX-AV Trial Results in JSCAI

Jan 13, 2025, 8:00 AM EST - 1 year ago

AngioDynamics Announces Publication of APEX-AV Trial Results in JSCAI

AngioDynamics: A Surgical Approach To Market Growth

Jan 8, 2025, 5:15 PM EST - 1 year ago

AngioDynamics: A Surgical Approach To Market Growth

AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Transcript

Jan 8, 2025, 11:00 AM EST - 1 year ago

AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Transcript

AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results

Jan 8, 2025, 6:30 AM EST - 1 year ago

AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results

AngioDynamics to Present at the J.P. Morgan Healthcare Conference

Jan 6, 2025, 9:26 AM EST - 1 year ago

AngioDynamics to Present at the J.P. Morgan Healthcare Conference

AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnifeâ„¢ System

Jan 6, 2025, 9:25 AM EST - 1 year ago

AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnifeâ„¢ System

AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event

Dec 19, 2024, 5:00 PM EST - 1 year ago

AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event

AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation

Dec 9, 2024, 6:00 AM EST - 1 year ago

AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation

AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System

Oct 23, 2024, 8:00 AM EDT - 1 year ago

AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System

AngioDynamics Announces American Medical Association's CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver

Oct 21, 2024, 8:00 AM EDT - 1 year ago

AngioDynamics Announces American Medical Association's CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver

AngioDynamics, Inc. (ANGO) Q1 2025 Earnings Call Transcript

Oct 3, 2024, 10:29 AM EDT - 1 year ago

AngioDynamics, Inc. (ANGO) Q1 2025 Earnings Call Transcript

AngioDynamics, Ingevity, Levi Strauss And Other Big Stocks Moving Lower On Thursday

Oct 3, 2024, 10:02 AM EDT - 1 year ago

AngioDynamics, Ingevity, Levi Strauss And Other Big Stocks Moving Lower On Thursday

LEVI NGVT

AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results

Oct 3, 2024, 6:30 AM EDT - 1 year ago

AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results

ZacksResearch
ZacksResearch Mar. 11 at 4:43 PM
Why $ANGO's growth story is just beginning! 🚀 With $ANGO's NanoKnife seeing revenue jump 22.2% YoY, driven by prostate cancer procedure adoption. Plus, the Auryon franchise reported its 18th straight quarter of double-digit growth in the second quarter. Discover why ANGO could continue to outperform 👉 https://www.zacks.com/stock/news/2882503/reasons-to-add-angiodynamics-stock-to-your-portfolio-for-now?cid=sm-stocktwits-2-2882503-body-37022&ADID=SYND_STOCKTWITS_TWEET_2_2882503_BODY_37022
0 · Reply
ZacksResearch
ZacksResearch Mar. 11 at 3:43 PM
$ANGO is gaining serious momentum — and the story might just be getting started. 👀 Strong fiscal Q2 results, surging NanoKnife adoption in prostate cancer, and broad Med Tech growth are all helping support margins and strengthen the investment case. See why ANGO could deserve a spot in your portfolio 👉 https://www.zacks.com/stock/news/2882503/reasons-to-add-angiodynamics-stock-to-your-portfolio-for-now?cid=sm-stocktwits-2-2882503-teaser-37012&ADID=SYND_STOCKTWITS_TWEET_2_2882503_TEASER_37012
0 · Reply
Estimize
Estimize Mar. 11 at 10:03 AM
Wall St is expecting -0.11 EPS for $ANGO Q3 [Reporting 04/02 BMO] http://www.estimize.com/intro/ango?chart=historical&metric_name=eps&utm_c
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 4 at 12:51 PM
$ANGO RSI: 50.52, MACD: 0.0938 Vol: 0.38, MA20: 11.05, MA50: 11.26 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ZacksResearch
ZacksResearch Feb. 23 at 6:14 PM
$ANGO just widened its oncology footprint in Europe — and that’s a big deal. AngioDynamics expanded NanoKnife’s EU indications to include liver, pancreas, kidney and prostate tumors, significantly broadening its reach and growth runway in multi-organ tumor ablation. That’s meaningful expansion, not incremental progress. Could this unlock the next leg of growth? Get the full breakdown 👉 https://www.zacks.com/stock/news/2873809/ango-expands-nanoknife-in-europe-for-multi-organ-tumor-ablation?cid=sm-stocktwits-2-2873809-teaser-34767&ADID=SYND_STOCKTWITS_TWEET_2_2873809_TEASER_34767
0 · Reply
ZacksResearch
ZacksResearch Feb. 23 at 5:14 PM
$ANGO gains on expanded NanoKnife approval in Europe! 🚀 Broader approvals for liver, pancreas, kidney, and prostate tumors open up significant market potential, reinforcing NanoKnife as a versatile oncology platform. 📈 With Europe contributing to 28% of global IRE volumes, ANGO is set for growth. Discover the full story here 👉 https://www.zacks.com/stock/news/2873809/ango-expands-nanoknife-in-europe-for-multi-organ-tumor-ablation?cid=sm-stocktwits-2-2873809-body-34751&ADID=SYND_STOCKTWITS_TWEET_2_2873809_BODY_34751
0 · Reply
TheWolfOfSanFran
TheWolfOfSanFran Feb. 23 at 2:50 AM
$ANGO m&A target possibly. 👀
0 · Reply
Estimize
Estimize Feb. 19 at 11:24 PM
Wall St is expecting -0.11 EPS for $ANGO Q3 [Reporting 04/02 BMO] http://www.estimize.com/intro/ango?chart=historical&metric_name=eps&utm_c
0 · Reply
OpenOutcrier
OpenOutcrier Feb. 19 at 2:01 PM
$ANGO (+2.4% pre) AngioDynamics gains European approval for NanoKnife tumor treatment https://ooc.bz/l/93907
0 · Reply
DARKP00L
DARKP00L Feb. 19 at 1:49 PM
$ANGO 08:43 on Feb. 19 2026 AngioDynamics Expands European Indications For NanoKnife System To Include Soft Tissue Ablation For Tumors Of Liver, Pancreas, Kidney, And Prostate #tradeideas
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 18 at 9:51 PM
$ANGO Share Price: $11.13 Contract Selected: Jul 17, 2026 $10 Calls Buy Zone: $1.15 – $1.42 Target Zone: $2.16 – $2.64 Potential Upside: 78% ROI Time to Expiration: 148 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
SolarWind
SolarWind Feb. 3 at 1:35 PM
$ANGO https://investors.angiodynamics.com/news-releases/news-release-details/angiodynamics-convene-cardiovascular-leaders-scientific-forum
0 · Reply
ZacksResearch
ZacksResearch Jan. 29 at 6:29 PM
$ANGO up 9.8% in 6 months — is the growth sustainable? 🚀 NanoKnife revenue jumped 22.2% YoY in Q2 FY26, driven by record prostate cancer procedure volumes, while the Auryon franchise saw an impressive 18.6% YoY revenue boost! Find out what could drive ANGO’s next breakout 👉 https://www.zacks.com/stock/news/2825594/reasons-to-add-angiodynamics-stock-to-your-portfolio-for-now?cid=sm-stocktwits-2-2825594-body-31059&ADID=SYND_STOCKTWITS_TWEET_2_2825594_BODY_31059
0 · Reply
ZacksResearch
ZacksResearch Jan. 29 at 5:29 PM
Why ANGO is back on my radar right now. 📈 $ANGO is being buoyed by strong fiscal Q2 results, surging NanoKnife adoption in prostate cancer, and broad Med Tech growth that’s supporting margins — a solid combo in this tape. See why the setup looks attractive here 👉 https://www.zacks.com/stock/news/2825594/reasons-to-add-angiodynamics-stock-to-your-portfolio-for-now?cid=sm-stocktwits-2-2825594-teaser-31048&ADID=SYND_STOCKTWITS_TWEET_2_2825594_TEASER_31048
0 · Reply
alfredaita
alfredaita Jan. 25 at 5:28 PM
$ANGO short interest to float high, significant amount of shares owned by Millennium and Izzy Englander. Seems like an Ethical individual. My guess is they may assist in finding a CEO replacement. Tariff relief would help.
0 · Reply
Estimize
Estimize Jan. 22 at 11:42 PM
Wall St is expecting -0.11 EPS for $ANGO Q3 [Reporting 04/02 BMO] http://www.estimize.com/intro/ango?chart=historical&metric_name=eps&utm_c
0 · Reply
SolarWind
SolarWind Jan. 15 at 8:56 PM
$ANGO over $35 in the next two years...
1 · Reply
Estimize
Estimize Jan. 14 at 11:45 AM
Wall St is expecting -0.11 EPS for $ANGO Q3 [Reporting 04/02 BMO] http://www.estimize.com/intro/ango?chart=historical&metric_name=eps&utm_c
0 · Reply
SolarWind
SolarWind Jan. 13 at 7:17 PM
$ANGO It's candle stick Hammer Time.
0 · Reply
ZacksResearch
ZacksResearch Jan. 13 at 7:03 PM
Margin quality is improving in MedTech — and these 3 names are leading it. 📈 $ANGO, $BSX, and $MDT are seeing earnings quality improve as higher-margin products take share, supporting stronger margins and more durable growth across the MedTech space. See why product mix is becoming a key driver for these stocks 👉 https://www.zacks.com/stock/news/2816795/3-medtech-stocks-benefiting-from-favorable-product-mix-shifts?cid=sm-stocktwits-2-2816795-teaser-28741&ADID=SYND_STOCKTWITS_TWEET_2_2816795_TEASER_28741
0 · Reply
alfredaita
alfredaita Jan. 8 at 7:10 PM
$ANGO stock dives on earnings day as Jim Clemens set to retire once replacement found. But this was already known as of 12/23 if not sooner. Strange
0 · Reply
hohumStocks
hohumStocks Jan. 8 at 7:05 PM
$ANGO Looks like a discount and value at current level with recent overreaction post positive earnings. I’m in with a big position here! Let’s see what happens.
0 · Reply